Normax Biomed

Normax Biomed is a pioneering company focused on the research, development, and manufacturing of mRNA vaccines and diagnostics aimed at combating infectious diseases such as Tuberculosis (TB) and HIV. The company operates within the global healthcare market, serving both public and private sectors, including governments, healthcare providers, and impact investors. Normax's business model revolves around the production and sale of low-cost mRNA vaccines, lateral flow tests, and affordable treatments. Additionally, the company offers mobile Electronic Health Record (EHR) data recording services that comply with HIPAA and GDPR regulations, and conducts local vaccine confidence education campaigns. Normax generates revenue through advance purchase agreements, strategic partnerships, and its flagship product, IPO.Vax, which is a modular factory deployment for GMP manufacturing of mRNA vaccines. The company has assembled the mRNA UCV Consortium, comprising over 25 industry leaders, engineering specialists, and financial experts, to drive innovation and delivery of mRNA vaccines for both human and animal health. Normax aims to end the transmission of TB and HIV by 2050, potentially saving 72 million lives and $3.9 trillion in healthcare costs. The company is also planning a U.S. IPO on Nasdaq to further its mission.

Keywords: mRNA vaccines, diagnostics, infectious diseases, Tuberculosis, HIV, healthcare, impact investors, EHR, GMP manufacturing, UCV Consortium.